Trying to rid the world of cancer seems to be a never-ending battle. This disease has been around for quite some time, and it has taken the lives of millions. Cancer research and cancer treatments are the name of the game. Dr. Clay Siegall has dedicated his life to fighting this illness. This is a 24/7 kind of job and no one takes it more serious than Siegall. On the other hand, Seattle Genetics is at the top of the ranks when it comes to this subject, and it produces some of the best cancer fighting medications. Antibody-drug conjugates have changed the game in the 21st century and Siegall has complete control of it all.
Seattle Genetics came into existence in 1998. At the time, it was a small startup company in the Pacific Northwest. The company struggled in its first few years, but as of today, it’s the worldwide leader in antibody-based therapies. Siegall has introduced many important factors into the business. This includes scientific innovation, drug development and rigorous research. Nothing is left to chance, especially if it deals with human health. The company’s premier drug is now being used across the globe in over 65 countries. ADCETRIS has created a huge revenue stream and as of now, this advanced medication has made well-over $350 million. The ability to enter this medication into strategic deals has been a huge success as it has distribution rights with Genentech, Bayer and GlaxoSmithKline.
It took Seattle Genetics at least 10 years before it started to make big gains. After securing its IPO, the company has skyrocketed straight to the top. Siegall’s importance to Seattle Genetics can’t questioned, and it can’t be denied. His superior knowledge-base comes from George Washington University and the University of Maryland. Siegall has won philanthropic awards, he owns up to 15 patents, and he has written 70 publications. In conclusion, Dr. Clay Siegall is the epitome of excellence, innovation and Seattle Genetics.